RNAPc2 in ACS, Results of ANTHEM-TIMI 32. June 22, 2007
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Novel Anti-thrombin Data Published
June 22, 2007 By Sabina A. Murphy, M.P.H. [1]
Boston MA, USA: The ANTHEM–TIMI-32 study of the novel anti-thrombin, recombinant NAPc2, an inhibitor of the tissue factor/factor VIIa complex, showed promise in reducing ischemia with higher doses of the drug compared with placebo, but did not eliminate the need for heparin in the setting of PCI for non-ST elevation ACS. The trial was published this week in the Journal of the American College of Cardiology.
The study was a randomized trial of rNAPc2 compared with placebo in 255 patients with non-ST elevation ACS undergoing an early invasive strategy with angiography. In the second phase of the trial, all patients received high-dose rNAPc2 with or without UFH to determine if thrombin inhibition with rNAPc2 would be sufficient to eliminate the need for heparin.
There was no excess bleeding with rNAPc2 until the highest dose group, which had all 4 of the major bleeds in the trial. The primary endpoint of major or minor bleeding occurred in 3.7% of the rNAPc2 group and 2.5% of the placebo group (p=NS). Ischemia on continuous ECG monitoring was improved in the higher dose rNAPc2 groups compared with placebo.
In the open-label portion of the study in which all patients received rNAPc2 and patients were randomized to no heparin or half-dose UFH, thrombotic bailout occurred more often in the no heparin group (19% vs. 0%; p = 0.051). Intracoronary thrombus formed during PCI in 4 of the 5 cases of thrombotic bailout.
The trial was funded by Nuvelo, Inc.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
